Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anika Therapeutics reports strong Q4 earnings, eyes growth opportunities

Anika Therapeutics delivered strong financial performance in Q4 2022, with revenue growth and strategic investments driving growth targets for 2023. The company is focused on product launches, expanding its portfolio, and preparing for the launch of the RevoMotion Reverse Shoulder System.
While facing challenges such as higher stock-based compensation and lower EBITDA expected in 2023, Anika remains optimistic about the value inflection point in 2023. The company's emphasis on growth initiatives and commercial optimization positions it for future opportunities.

Anika Therapeutics reports growth in core segments and strategic investments

Anika Therapeutics showed positive revenue growth in Q1, driven by core business segments.
Despite a net loss, Anika is strategically positioning itself as a global leader in joint preservation.
Investments in new products and regulatory progress with Cingal indicate a focus on innovation and expansion.
Maintaining strong gross margins amidst increased operating expenses highlights operational efficiency.

Anika Therapeutics posts robust Q2 results, eyes growth opportunities

Anika Therapeutics reported strong Q2 results, raising its revenue outlook for 2023.
Despite international challenges, the company sees opportunities for growth in key segments.
Progress in FDA approvals, partnerships, and new product launches position Anika for future success.
Maintaining a focus on innovation and market expansion will be crucial for sustained growth.

Anika Therapeutics raises guidance on strong Q3 performance and outlook

Anika Therapeutics showcased robust growth in key segments, leading to an optimistic outlook for the year. Despite challenges in restructuring sales operations, the company is well-positioned for continued success with a focus on profitability and new product launches.

Anika Therapeutics exceeds Q4 expectations, eyes Hyalofast's U.S. potential

Anika Therapeutics delivered robust financial performance, focusing on driving new products for growth and operational efficiency. The company aims to accelerate profitability targets and is on track with product launches, making strategic adjustments based on feedback.

Anika Therapeutics reports Q1 revenue growth and strategic product advancements

Anika Therapeutics demonstrated solid financial performance in Q1 2024, driven by revenue growth, cost reduction initiatives, and positive market feedback on key products.
While facing challenges such as FDA approval requirements and leadership transition, the company's strengths in product portfolio and distribution agreements position it well for future growth.
Opportunities in FDA designations, revenue growth expectations, and operational improvements present avenues for Anika to enhance market presence and financial performance in the coming quarters.

Anika Therapeutics reports Q3 revenue, focuses on core products

Anika Therapeutics faces challenges with workforce reduction and financial losses
However, strategic focus on core HA products and revenue reclassification show promise
Opportunities lie in revenue growth in the commercial channel and long-term investments
Overall, Anika Therapeutics aims for sustainable growth and value creation

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

X-Twist provides a simple, versatile knotless suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremities X-Twist provides a simple, versatile knotless suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremities

Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

BEDFORD, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the UBS Global Healthcare Conference 2022 being held in-person at the Lotte New York Palace, New York, NY, on Wednesday, May 25, 2022. Anika will host a live presentation with fireside chat starting at 11:30am ET. Management will also be participating in 1x1 investor meetings on the same day.

Anika to Participate in the UBS Global Healthcare Conference 2022

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Mark Namaroff - VP, IR, ESG and Corporate Communications Cheryl Blanchard - President and CEO Mike Levitz - EVP, CFO and Treasurer Conference Call Participants Chris Cooley - Stephens Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's First Quarter 2022 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corporate Communications.

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q1 2022 Results - Earnings Call Transcript

First quarter revenue growth of 7% year-over-year driven by favorable order timing in OA Pain Management First quarter revenue growth of 7% year-over-year driven by favorable order timing in OA Pain Management

Anika Reports First Quarter Fiscal 2022 Financial Results

BEDFORD, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2022 financial results after the close of the market on Thursday, May 5, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue First Quarter 2022 Financial Results on Thursday, May 5, 2022

Ampio Pharmaceuticals Inc

FAT Brands

AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.

New Strong Sell Stocks for April 7th

BEDFORD, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022. Anika will host a live presentation starting at 8:00am ET. Management will also be participating in 1x1 investor meetings on the same day.

Anika to Participate in the 21st Annual Needham Virtual Healthcare Conference

Anika is an innovative joint preservation company focused on the early intervention orthopedic continuum of care including OA pain management, regenerative solutions, sports medicine, and bone preserving joint technologies. Anika is an innovative joint preservation company focused on the early intervention orthopedic continuum of care including OA pain management, regenerative solutions, sports medicine, and bone preserving joint technologies.

Anika to Showcase its Transformation into a Global Leader in Joint Preservation during the 2022 AAOS Annual Meeting

Anika Therapeutics' share price is being punished by the market owing to some possibly over-ambitious growth projections made in June last year.

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Anika Therapeutics Inc's (ANIK) CEO Cheryl Blanchard on Q4 2021 Results - Earnings Call Transcript

Fourth quarter revenue growth of 10% year-over-year despite COVID headwinds Full-year 2021 revenue up 13% driven by strong growth in Joint Preservation and Restoration

Anika Reports Fourth Quarter and Year-End 2021 Financial Results

BEDFORD, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2021 financial results after the close of the market on Tuesday, March 8, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022

Anika Therapeutics' (ANIK) CEO Cheryl Blanchard on Q3 2021 Results - Earnings Call Transcript

Anika (ANIK) delivered earnings and revenue surprises of 144.44% and 8.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Tops Q3 Earnings and Revenue Estimates

Appointment brings experienced orthopedic industry commercial leader to Anika's Board Appointment brings experienced orthopedic industry commercial leader to Anika's Board

Anika Appoints Sheryl Conley to Board of Directors

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anika Therapeutics (ANIK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Designed to preserve natural motion and maximize stability, the WristMotion® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion Designed to preserve natural motion and maximize stability, the WristMotion® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion

Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting

510(k) clearance expands the capability of Tactoset for augmenting suture anchor fixation 510(k) clearance expands the capability of Tactoset for augmenting suture anchor fixation

Tactoset® Injectable Bone Substitute Now FDA Cleared for Hardware Augmentation

BEDFORD, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 15, 2021 at 2:00 p.m. ET.

Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Anika, now combined with Arthrosurface and Parcus Medical, meets the evolving unmet needs of surgeons in the global joint preservation market Anika, now combined with Arthrosurface and Parcus Medical, meets the evolving unmet needs of surgeons in the global joint preservation market

Anika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting

Anika Therapeutics' (ANIK) CEO Cheryl Blanchard on Q2 2021 Results - Earnings Call Transcript

BEDFORD, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2021 financial results after the close of the market on Thursday, August 5, 2021 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021

BEDFORD, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to host its 2021 Virtual Investor Day on Thursday, June 3, 2021 beginning at 9:00am EDT.

Anika to Host its 2021 Virtual Investor Day on June 3, 2021

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q1 2021 Results - Earnings Call Transcript

Anika (ANIK) delivered earnings and revenue surprises of 225.00% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Anika Therapeutics Stock (ANIK)